来凯医药有限公司（下称“公司”，股票代码：02105）于2026年3月5日提交截至2026年2月28日的股份变动月报表。报告显示，公司法定股本维持5,000,000,000股，每股面值0.00001美元，总额50,000美元。截至2026年2月底，普通股已发行股份总数为446,466,350股，较上月底无增加或减少。
根据公司披露，本月内未发生股份发行、购回或注销行为，库存股数量保持为0。此外，针对首发前及首发后购股权计划，报告期内无新股因行使期权而发行，亦无期权相关的库存股转让。本月底普通股已发行股份总数保持不变，公司确认已满足香港联交所上市规则要求的公众持股比例。
公司同时表示，本月所有股份及相关操作均获得董事会正式授权，并已遵守适用上市规则与相关法律规定。本次月报由联席公司秘书柯晨煜签署。公司股本结构整体维持稳定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.